Thrombolytic treatment of acute ischemic stroke

Mayo Clinic Proceedings

Volumn 77, Issue 6, 2002, Pages 542-551

  Meschia, James F ^a   Miller, David A ^a   Brott, Thomas G ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ALTEPLASE; ARGATROBAN; FIBRINOLYTIC AGENT; HEPARIN; PROUROKINASE;

ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CHRONOLOGY; CLINICAL TRIAL; DRUG INDICATION; EARLY DIAGNOSIS; FIBRINOLYTIC THERAPY; HUMAN; MEDICAL DECISION MAKING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; STROKE;

EID: 0036264097     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/77.6.542     Document Type: Article

References (64)

1. Comparable studies of the incidence of stroke and its pathological types: Results from an international collaboration
2. Mortality and causes of death after first ischemic stroke: The Northern Manhattan Stroke Study
3. Tissue plasminogen activator reduces neurological damage after cerebral embolism
4. Reduction of infarct volume and mortality by thrombolysis in a rat embolic stroke model
5. Reduction of infarct volume by thrombolysis with rt-PA in an embolic rat stroke model
6. Experimental thromboembolic stroke studied by positron emission tomography: Immediate versus delayed reperfusion by fibrinolysis
7. The beneficial effect of intracarotid urokinase on acute stroke in a baboon model
8. Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours
9. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke
10. Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolic stroke
11. PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke
12. Tissue plasminogen activator for acute ischemic stroke
13. Effects of tissue plasminogen activator for acute ischemic stroke at one year
14. Early stroke treatment associated with better outcome: The NINDS rt-PA stroke study
15. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Acute Stroke Study (ECASS)
16. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
17. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): Results of a double-blind, placebo-controlled, multicenter study
18. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset: The ATLANTIS Study: A randomized controlled trial
19. ATLANTIS trial: Results for patients treated within 3 hours of stroke onset
20. Guidelines for Thrombolytic Therapy for Acute Stroke: A Supplement to the Guidelines for the Management of Patients with Acute Ischemic Stroke: A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association
21. Practice advisory: Thrombolytic therapy for acute ischemic stroke - Summary statement: Report of the Quality Standards Subcommittee of the American Academy of Neurology
22. Use of tissue-type plasminogen activator for acute ischemic stroke: The Cleveland area experience
23. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000
24. Extending tissue plasminogen activator use to community and rural stroke patients
25. Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage
26. Effectiveness of t-PA in acute ischemic stroke: Outcome relates to appropriateness
27. Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: A multicenter survey
28. Alteplase for stroke: Money and optimistic claims buttress the "brain attack" campaign
29. Subgroup analysis and other (mis)uses of baseline data in clinical trials
30. Commentary: Thrombolysis in stroke: It works!
31. Thrombolytic therapy for acute ischemic stroke: Why the majority of patients remain ineligible for treatment
32. A systems approach to immediate evaluation and management of hyperacute stroke: Experience at eight centers and implications for community practice and patient care
33. Recommendations for improving the quality of care through stroke centers and systems: An examination of stroke center identification options: Multidisciplinary consensus recommendations from the Advisory Working Group on Stroke Center Identification Options of the American Stroke Association
34. Cranial computed tomography interpretation in acute stroke: Physician accuracy in determining eligibility for thrombolytic therapy
35. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke
36. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke
37. European strategies for early intervention in stroke: A report of an Ad Hoc Consensus Group meeting
38. Hypertension and its treatment in the NINDS rt-PA Stroke Trial
39. Randomised controlled trial of streptokinase, aspirin; and combination of both in treatment of acute ischaemic stroke
40. Intra-arterial prourokinase for acute ischemic stroke: The PROACT II study: A randomized controlled trial
41. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: The PROACT II trial
42. Local intraarterial thromholysis in vertebrobasilar thromboembolic disease
43. Thrombolytic therapy of acute basilar artery occlusion: Variables affecting recanalization and outcome
44. Local intra-arterial fibrinolysis in vertebro-basilar thrombosisprognostic criteria
45. Survival with basilar artery occlusion
46. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial
47. Selective and superselective infusion of urokinase for embolic stroke
48. Safety and efficacy of delayed intraarterial urokinase therapy with mechanical clot disruption for thromboembolic stroke
49. Combined intraarterial/intravenous thrombolysis for acute ischemic stroke
50. Thrombolytic therapy: Foundations and clinical results
51. Physiologic regulation and pathologic disorders of fibrinolysis
52. Hemorrhagic transformations in MAST-E trial: Predictive factors
53. The clinical utility of spiral computed tomographic angiography in the evaluation of carotid artery disease: Review of our first 50 patients
54. Potential of CT angiography in acute ischemic stroke
55. CT angiography in the evaluation of acute stroke
56. CT angiography and Doppler sonography for emergency assessment in acute basilar artery ischemia
57. CT angiography in acute ischemic stroke: Preliminary results
58. Clinical sensitivity and specificity of diffusion weighted MRI in hyperacute stroke
59. Utility of diffusion weighted MRI in acute stroke
60. Significance of early CT signs in acute stroke: A CT scan-diffusion MRI study
61. Fluidattenuated inversion recovery and diffusion- and perfusion-weighted MRI abnormalities in 117 consecutive patients with stroke symptoms
62. A three-item scale for the early prediction of stroke recovery
63. Severe ADC decreases do not predict irreversible tissue damage in humans